qXR-CTR vs iPredict Eye Screening

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

qXR-CTR

by Qure.ai Technologies

iPredict Eye Screening

by iHealthScreen

AI Verdict

While both tools leverage AI for disease screening and include cardiovascular risk assessment, qXR-CTR specifically focuses on automated cardiothoracic ratio measurement from chest X-rays for heart size and heart failure risk. iPredict Eye Screening, on the other hand, primarily screens for ophthalmic conditions like AMD, DR, and Glaucoma, with an additional feature for systemic disease risk prediction including stroke and heart attack based on retinal analysis. Therefore, qXR-CTR is more suitable for direct cardiac assessment via radiology, while iPredict Eye Screening offers broader screening for retinal and systemic risks through ophthalmology.

Choose qXR-CTR if…

Choose qXR-CTR if your primary need is automated, precise measurement of the cardiothoracic ratio from chest X-rays to assess heart size and identify potential heart failure risk. This tool is ideal for radiology and cardiology departments seeking to enhance diagnostic accuracy and efficiency in evaluating cardiac conditions from standard chest radiographs.

View qXR-CTR →

Choose iPredict Eye Screening if…

Choose iPredict Eye Screening if your focus is on comprehensive, AI-powered screening for multiple retinal and systemic diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, particularly in primary care settings. This tool is well-suited for clinics and hospitals aiming for early detection of these conditions and risk prediction for stroke and heart attack, with fast, automated results and EHR integration.

View iPredict Eye Screening →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	qXR-CTR	iPredict Eye Screening
Pricing	Contact for pricing	Contact for pricing
Deployment	Cloud, on-premise, hybrid	Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps.
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

iPredict Eye Screening

iPredict Eye Screening emphasizes ease of use with a fast, non-invasive test completed in under 5 minutes and reports generated in under 60 seconds, along with an advanced touchscreen interface. While qXR-CTR focuses on seamless integration into existing radiology workflows and provides AI overlays and structured reports, it does not explicitly detail the user interface or overall ease of operation for non-specialists.

Clinical Value

iPredict Eye Screening

iPredict Eye Screening offers a broader clinical value by screening for multiple conditions (AMD, DR, Glaucoma) and providing risk prediction for systemic diseases like stroke and heart attack, with reported high accuracy (e.g., AMD sensitivity 86.86%, specificity 94.13%). qXR-CTR focuses on automated cardiothoracic ratio measurement for heart failure risk, which is a valuable but more singular application.

Pricing & Value

iPredict Eye Screening

iPredict Eye Screening provides an estimated per-patient screening cost ($10-$20), offering some transparency and a clear SaaS model. qXR-CTR's pricing is not publicly disclosed, requiring direct contact for information, which makes it harder to assess its value proposition without further inquiry.

Enterprise Readiness

qXR-CTR

qXR-CTR, as part of Qure.ai's broader qXR platform, integrates with major PACS and modalities (GE, Philips, Siemens, etc.) and offers various deployment options (cloud, on-premise, hybrid), indicating strong enterprise readiness. iPredict Eye Screening mentions EHR integration and telemedicine services, but less detail is provided on its broader integration capabilities with diverse hospital IT infrastructures.

Innovation

iPredict Eye Screening

iPredict Eye Screening demonstrates significant innovation by being the first company to receive two US patents for AMD and glaucoma screenings and by offering risk prediction for systemic diseases from retinal images. qXR-CTR is innovative in automating CTR measurement and is part of Qure.ai's extensive portfolio of FDA-cleared algorithms, but iPredict's multi-disease screening and systemic risk prediction from a single image source appear to be a more novel approach.

Support & Docs

qXR-CTR

Qure.ai, the company behind qXR-CTR, provides comprehensive documentation, including user manuals for its Qure.ai app, and offers various support channels like email, phone, chat, and 24x7 availability. While iHealthScreen's iPredict is FDA-cleared and has undergone clinical trials, specific details regarding their customer support channels and public documentation are not as readily available.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	qXR-CTR	iPredict Eye Screening
Tool Name	qXR-CTR	iPredict Eye Screening
Company	Qure.ai Technologies	iHealthScreen
Description	AI-powered software that automates the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, aiding in the assessment of heart size and potential heart failure risk.	FDA-cleared AI-powered screening tool for age-related macular degeneration (AMD) in patients aged 50 years and older, alongside screening for Diabetic Retinopathy (DR) and Glaucoma. The platform also provides risk prediction for systemic diseases like stroke and heart attack, integrating with EHR and telemedicine services.
Primary Categories	Cardiology AI, Radiology & Imaging AI	Cardiology AI, Neurology AI, Ophthalmology AI
Key Features	Not specified	AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma; Electronic Health Record (EHR) Solutions; AI-Based Telemedicine Service; Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector; Online Health Risk Prediction System for Diabetic, Stroke, and Heart Attack patients; Fast results: test completed in less than 5 minutes, report in under 60 seconds; High accuracy: approximately 95% on average (AMD sensitivity 86.86%, specificity 94.13%); Easy to operate, non-invasive, with an advanced touchscreen interface

Videos

Demos, reviews, and walkthroughs featuring qXR-CTR and iPredict Eye Screening.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

qXR-CTR is designed to integrate seamlessly into existing radiology workflows, providing annotated X-rays and structured reports in DICOM and JSON formats. It also offers features like worklist management and pre-filled radiology reports. iPredict Eye Screening integrates with EHR and telemedicine services, providing fully automated reports in less than 60 seconds after images are captured with a color fundus camera.

What are the accuracy and sensitivity metrics for each tool in detecting relevant conditions?

qXR-CTR's performance testing showed a Root Mean Squared Error for cardiac diameter at 7.55 mm and thoracic diameter at 5.43 mm. iPredict Eye Screening boasts an average accuracy of approximately 95%. Specifically, for AMD, it has a sensitivity of 86.86% and a specificity of 94.13%. For diabetic retinopathy, iPredict achieved up to 98.48% accuracy with 97.32% sensitivity and 98.75% specificity for referable DR. For glaucoma suspect, it achieved 89.67% accuracy with 83.33% sensitivity and 93.89% specificity.

Which specialties are these tools best suited for, and what clinical context should I consider?

qXR-CTR is primarily suited for Cardiology and Radiology, aiding in the assessment of heart size and potential heart failure risk from chest X-rays. iPredict Eye Screening is designed for Family Medicine, Internal Medicine, and Ophthalmology, offering screening for age-related macular degeneration, diabetic retinopathy, and glaucoma, as well as risk prediction for systemic diseases like stroke and heart attack.

What is the typical learning curve for physicians and their staff to effectively use these tools?

iPredict Eye Screening is described as easy to operate, with the entire test completed in less than 5 minutes and results in under 60 seconds, suggesting a minimal learning curve for staff. For qXR-CTR, while not explicitly stated, its integration into existing radiology workflows and provision of structured reports implies it's designed for efficient adoption within a familiar environment.

What audit-trail features do these tools offer to ensure accountability and track usage?

While specific audit-trail features are not detailed for qXR-CTR, its integration with existing radiology workflows and generation of structured reports in DICOM and JSON formats would typically support traceability within a clinical setting. For iPredict Eye Screening, the system provides fully automated reports after image capture, which inherently creates a record of the screening event and its results.

How quickly can a practice expect to see value after implementing these tools?

iPredict Eye Screening offers fast results, with tests completed in under 5 minutes and reports generated in less than 60 seconds, indicating a rapid time-to-value for screening and immediate actionable results. qXR-CTR provides high-volume, low-latency processing, typically under 20 seconds, which can significantly reduce turnaround time for chest X-ray interpretations and aid in quicker diagnoses.

Are there customer references or case studies available to demonstrate real-world effectiveness and multi-site rollout considerations?

iPredict Eye Screening has screened over 5000 patients for DR and over 3000 for AMD globally, indicating real-world usage across multiple continents. qXR-CTR's broader qXR platform has been clinically validated in multiple geographies and integrated into routine workflows for evaluating over 65,000 chest X-rays, demonstrating strong overall performance and reduced turnaround times.